ClinicalTrials.gov
public full text
Public Domain
Mechanisms of Lorcaserin for Smoking Cessation
Identifying new medication options is critical for curbing the health burdens of cigarette smoking. Currently approved smoking cessation medications act on nicotinic receptors, and additional work is needed to identify medications with alternate pharmacological targets. Based on evidence that the serotonin system plays a role in nicotine consumption and relapse, this study will examine whether a selective serotonin medication alters smoking-related behaviors and responses to cigarette smoking under controlled conditions, informing its potential utility for smoking cessation.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Laboratory Screening of Lorcaserin for Alcohol Use Disorder#969656
- EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking#865818
- Combining Varenicline and Bupropion for Smoking Cessation#915470
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit#843438
- Efficacy and Safety of Varenicline Among HIV-infected Patients#857940
Record · ID 833130
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive